For people living with both HIV and hepatitis C virus (HCV), not only
does curative hepatitis C treatment reduce the risk of liver-related
disease and death, but it also helps limit HIV disease progression and
deaths not related to liver disease, according to a Spanish study published ahead of print by Clinical Infectious Diseases.
studies have demonstrated that a sustained virologic response (SVR) to
hepatitis C therapy—an HCV viral load that remains undetectable for 24
weeks following completion of treatment, indicating that the infection
has been cured—improves liver scarring (fibrosis) and reduces the risk
of liver-related complications. This has been confirmed among people
living with only HCV, as well as those coinfected with both HCV and HIV.